Abdominal Aortic Aneurysm Treatment Market
Market Insights on Abdominal Aortic Aneurysm Treatment covering sales outlook, demand forecast & up-to-date key trends
Abdominal Aortic Aneurysm Treatment Market: Global Industry Analysis and Opportunity Assessment 2022-2032
Abdominal Aortic Aneurysm Treatment Market Outlook
The abdominal aortic aneurysm treatment market is expected to register a modest growth rate of 5.82% through the forecast period, rising in valuation from US$ 2.06 Bn in 2022 to US$ 3.63 Bn in 2032.
Market Valuation (2022)
US$ 2.06 billion
Market Valuation (2032)
US$ 3.63 billion
The abdominal aortic aneurysm treatment market could expand as a result of:
- Geriatric population growth.
- The prevalence of atherosclerosis, syphilis, and medical cystic necrosis is increasing.
- Technological advancements and the availability of medical device reimbursement.
- Rising research and development costs and rising healthcare costs.
- Hypertension and hyperlipidaemia are expected to drive the abdominal aortic aneurysm treatment market.
- The rising number of smokers, particularly elderly male smokers who require ultrasound screening in addition to pre-existing CT scans, is expected to drive the growth of the market.
Abdominal aortic aneurysm is the enlargement of lower part of aorta in the abdomen. The aorta is the main supplier of the blood to the body, hence the ruptured abdominal aortic aneurysm may cause abnormal bleeding. Abdominal aortic aneurysm is asymptomatic disorder unless there is a rupture which leads to internal bleeding and hemorrhaging.
The treatment of abdominal aortic aneurysm depends upon the size and enlargement of the aorta. Surgical intervention is advised if the aneurysm is larger than 55mm and occurs in people aged above 55 years. It is very rare in people of less than 60 years of age which provides significant evidence that this is an age related condition.
High cholesterol and blood pressure, diabetes, obesity, smoking also play an important role in the growing incidence of abdominal aortic aneurysm in people. The disorder is normally detected and diagnosed through an ultrasound of the abdomen but more detailed information can be provided by other modalities such as computed tomography scans for situations where location of the aneurysm is critical.
The mortality rate is around 75% is estimated if an aneurysm ruptures and causes internal bleeding
Current Treatment Landscape for Abdominal Aortic Aneurysms
There is currently no FDA-approved therapy for limiting the growth of an abdominal aortic aneurysm. If the aneurysm is less than 5 cm or 2 inches in diameter, the doctor may first try to treat it with medication. They may prescribe drugs to lower blood pressure and relax blood vessels, such as beta-blockers and calcium channel blockers. These medications will reduce the likelihood of an aneurysm rupture. Indeed, several therapeutic effects of pharmacological agents have been reported in animal models, and some agents have been tested in humans.
Treatment of abdominal aortic aneurysms with statins, angiotensin-converting enzyme inhibitors, antibiotics, and anti-inflammatory agents appears to slow the rate of growth in humans. The doctor will continue to check on the patient on a regular basis to see if the aneurysm is growing. Heavy lifting that puts pressure on the aorta should be avoided. Treatment for specific abdominal aortic aneurysms is based on age, overall health, medical history, the extent of the disease, signs and symptoms, tolerance to specific medications, procedures, or therapies, expectations for the disease's course, and opinion or preference.
Geographical analysis on the Abdominal Aortic Aneurysm Treatment Market
Geographically, North America has the largest market share due to the rising prevalence of atherosclerosis. Furthermore, increased research and development is boosting market growth. Europe is also expected to see an increase in the burden of cardiovascular disease, as well as increased market participant initiatives to expand their product distribution network. Due to rising awareness of advanced treatment options and market players' increased focus on emerging economies, Asia-Pacific is expected to account for the largest market share.
To address the current unmet needs in the abdominal aortic aneurysm treatment market and to provide better treatment options, several major pharmaceutical companies are working hard to develop new Abdominal Aortic Aneurysm emerging devices such as the Abdominal Aortic Aneurysm Stent Graft System (Lifetech Scientific), Fenestrated AlturaTM FEVAR Stent Graft (Lombard Medical), Seta Latecba Stent Grafts (Latecba SA The therapeutic options available in the Abdominal Aortic Aneurysm (AAA) landscape aim to reduce disease burden. There are numerous novel Abdominal Aortic Aneurysm devices in development, including -
On September 30, 2018, Lifetech Scientific launched a clinical trial to assess the safety and efficacy of the AAA Stent Graft System for infrarenal abdominal aortic aneurysms.
Endologix LLC, a vascular disease treatment leader, is developing the ChEVAS system, an endovascular abdominal aortic aneurysm therapy that combines the Nellix 3.5 endograft with parallel visceral stents to treat juxta-renal, pararenal, and suprarenal abdominal aortic aneurysms.
Abdominal Aortic Aneurysm Treatment Market: Drivers and Restraints
The incidence rate of abdominal aortic aneurysm is found to be increasing worldwide due to changes in lifestyle. Abdominal aortic aneurysm occurs commonly in men, four times more than in women.
The risk factors associated with abdominal aortic aneurysm are hypovolemic shock with low blood pressure and elevated heart rate due to which the awareness about the treatment is increasing.
The major factors facilitating the growth of abdominal aortic aneurysm treatment market are increase in geriatric population, increased incidence of hypertension and hyperlipidemia. The restraints of abdominal aortic aneurysm treatment market are cost of treatment and availability of treatment.
Abdominal Aortic Aneurysm Treatment Market: Overview
It is estimated that approximately 13,000 deaths occur yearly in U.S. due to abdominal aortic aneurysm rupture in the patients between 60 and 70 years of age. The frequency of disorder is much high in case of smokers as compared to that of non-smokers.
In the U.S. the incidence rate of abdominal aortic aneurysm is estimated to be approximately 2-4% of the adult population. Surgery is advised to the patients of abdominal aortic aneurysm, young patients being advised open surgery and geriatric patient are advised endovascular aneurysm.
Thus, the market for surgeries is expected to contribute majorly in the overall abdominal aortic aneurysm treatment market.
Abdominal Aortic Aneurysm Treatment Market: Regional Overview
Geographically, the global abdominal aortic aneurysm treatment is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is expected to be the highly lucrative market for abdominal aortic aneurysm treatment owing to the increased incidence rate of abdominal aortic aneurysm.
European countries are expected to contribute further in the global abdominal aortic aneurysm market in regards to the high geriatric population. However, the investment of the pharmaceutical industries in the R&D of drugs for treatment of abdominal aortic aneurysm are expected to fuel the growth of global abdominal aortic aneurysm treatment market.
Abdominal Aortic Aneurysm Treatment Market: Key Players
Some of the key players in abdominal aortic aneurysm treatment market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers, Abbott, AbbVie Inc., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc.,Sanofi, GlaxoSmithKline Pharmaceuticals Limited and Mylan N.V.
The report covers exhaustive analysis on
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Mexico, Brazil)
- Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
- Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
- Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
- Middle East and Africa (GCC countries, S. Africa, Rest Of MEA)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Abdominal Aortic Aneurysm Treatment Market: Segmentation
The global abdominal aortic aneurysm treatment market has been classified on the basis of treatment, end use and geography.
Based on treatment, the global abdominal aortic aneurysm treatment market is divided into following:
- Open surgery
- Endovascular aneurysm
Based on end user type, the global abdominal aortic aneurysm treatment market is divided into following: